$ATXI
Avenue Therapeutics Inc

2023 Q2 Form 10-Q Financial Statement

#000143774923014236 Filed on May 12, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $896.0K $984.0K $3.367M
YoY Change 97.36% -6.73% 542.56%
% of Gross Profit
Research & Development $3.027M $1.215M $300.0K
YoY Change 1904.64% -32.8% -23.08%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $3.027M $1.215M $300.0K
YoY Change 1904.64% -32.8% -67.18%
Operating Profit -$3.923M -$6.429M
YoY Change 548.43% 124.55%
Interest Expense $57.00K -$1.173M $4.436M
YoY Change 5600.0% -58750.0% 443500.0%
% of Operating Profit
Other Income/Expense, Net -$93.00K -$1.173M $5.580M
YoY Change -9400.0% -58750.0%
Pretax Income -$4.016M -$7.602M $524.0K
YoY Change 564.9% 165.71% -157.39%
Income Tax
% Of Pretax Income
Net Earnings -$4.016M -$7.602M $575.0K
YoY Change 564.9% 165.71% -162.98%
Net Earnings / Revenue
Basic Earnings Per Share -$0.52 -$1.35
Diluted Earnings Per Share -$0.52 -$1.35 $0.13
COMMON SHARES
Basic Shares Outstanding 7.920M 5.944M 4.773M
Diluted Shares Outstanding

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.571M $8.236M $6.708M
YoY Change 76.52% 349.32% 78.26%
Cash & Equivalents $1.571M $8.236M $6.708M
Short-Term Investments
Other Short-Term Assets $69.00K $198.0K $137.0K
YoY Change -40.0% 60.98% 28.04%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $1.666M $8.447M $6.845M
YoY Change 65.77% 331.85% 72.85%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00 $0.00
YoY Change -100.0%
TOTAL ASSETS
Total Short-Term Assets $1.666M $8.447M $6.845M
Total Long-Term Assets $0.00 $0.00 $0.00
Total Assets $1.666M $8.447M $6.845M
YoY Change 65.77% 331.85% 72.85%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $446.0K $330.0K $129.0K
YoY Change 52.22% -33.06% -57.57%
Accrued Expenses $1.494M $4.552M $633.0K
YoY Change 1210.53% 1397.37% 208.78%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $7.812M $10.60M $3.579M
YoY Change 1819.41% 1230.49% 603.14%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $7.812M $10.60M $3.579M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $7.812M $10.60M $3.579M
YoY Change 1819.41% 1230.49% 603.14%
SHAREHOLDERS EQUITY
Retained Earnings -$92.10M -$88.10M -$80.60M
YoY Change 14.41% 10.26% 4.68%
Common Stock $1.000K $1.000K $84.46M
YoY Change -100.0% -100.0% 4.98%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$5.336M -$1.452M $3.905M
YoY Change
Total Liabilities & Shareholders Equity $1.666M $8.447M $6.845M
YoY Change 65.77% 331.85% 72.85%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q4
OPERATING ACTIVITIES
Net Income -$4.016M -$7.602M $575.0K
YoY Change 564.9% 165.71% -162.98%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$4.665M -$1.573M -$4.169M
YoY Change 394.7% -18.5% 246.55%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$2.000M
YoY Change
Cash From Investing Activities -$2.000M
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 $3.101M 10.66M
YoY Change 143.32%
NET CHANGE
Cash From Operating Activities -4.665M -$1.573M -4.169M
Cash From Investing Activities -2.000M
Cash From Financing Activities 0.000 $3.101M 10.66M
Net Change In Cash -6.665M $1.528M 6.491M
YoY Change 606.79% -179.17% 104.25%
FREE CASH FLOW
Cash From Operating Activities -$4.665M -$1.573M -$4.169M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
3.30
CY2022 atxi Class Of Warrant Or Right Aggregate Intrinsic Value
ClassOfWarrantOrRightAggregateIntrinsicValue
1 usd
CY2023Q1 atxi Class Of Warrant Or Right Issued During Period
ClassOfWarrantOrRightIssuedDuringPeriod
3432598
CY2023Q1 atxi Class Of Warrant Or Right Granted During Period Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightGrantedDuringPeriodExercisePriceOfWarrantsOrRights
0.88
CY2023Q1 atxi Class Of Warrant Or Right Exercised During Period
ClassOfWarrantOrRightExercisedDuringPeriod
-400083
CY2023Q1 atxi Class Of Warrant Or Right Exercised During Period Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightExercisedDuringPeriodExercisePriceOfWarrantsOrRights
0
CY2023Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
7170431
CY2023Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.32
CY2023Q1 atxi Class Of Warrant Or Right Aggregate Intrinsic Value
ClassOfWarrantOrRightAggregateIntrinsicValue
1272 usd
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6828186
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6828186
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4773841
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4773841
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-38114
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-4113275
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
1111 Kane Concourse, Suite 301
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Bay Harbor Islands
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
33154
CY2023Q1 dei City Area Code
CityAreaCode
781
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
652‑4500
CY2023Q1 dei Security12b Title
Security12bTitle
Common Stock
CY2023Q1 dei Trading Symbol
TradingSymbol
ATXI
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
7920485
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8236000 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6708000 usd
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
198000 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
137000 usd
CY2023Q1 us-gaap Assets
Assets
8447000 usd
CY2022Q4 us-gaap Assets
Assets
6845000 usd
CY2023Q1 atxi Accrued Licenses Acquired Current
AccruedLicensesAcquiredCurrent
3000000 usd
CY2022Q4 atxi Accrued Licenses Acquired Current
AccruedLicensesAcquiredCurrent
0 usd
CY2023Q1 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
5722000 usd
CY2022Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
2609000 usd
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
10604000 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3579000 usd
CY2023Q1 us-gaap Liabilities
Liabilities
10604000 usd
CY2022Q4 us-gaap Liabilities
Liabilities
3579000 usd
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
1000 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
0 usd
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
86634000 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
84456000 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-88087000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-80551000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-1452000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
3905000 usd
CY2023Q1 us-gaap Minority Interest
MinorityInterest
-705000 usd
CY2022Q4 us-gaap Minority Interest
MinorityInterest
-639000 usd
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-2157000 usd
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
3266000 usd
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
8447000 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6845000 usd
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1215000 usd
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1808000 usd
CY2023Q1 atxi Research And Development Expense For Licenses Acquired
ResearchAndDevelopmentExpenseForLicensesAcquired
4230000 usd
CY2022Q1 atxi Research And Development Expense For Licenses Acquired
ResearchAndDevelopmentExpenseForLicensesAcquired
0 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
984000 usd
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1055000 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-6429000 usd
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2863000 usd
CY2023Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
37000 usd
CY2022Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
2000 usd
CY2023Q1 atxi Financing Costs Warrant Liabilities
FinancingCostsWarrantLiabilities
332000 usd
CY2022Q1 atxi Financing Costs Warrant Liabilities
FinancingCostsWarrantLiabilities
-0 usd
CY2023Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
878000 usd
CY2022Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-0 usd
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1173000 usd
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2000 usd
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-7602000 usd
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-2861000 usd
CY2023Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-66000 usd
CY2022Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-0 usd
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7536000 usd
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2861000 usd
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.35
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.05
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5564830
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1397145
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
3266000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
11000 usd
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
72000 usd
CY2023Q1 atxi Stock And Prefunded Warrants Issued During Period Value Private Placement Net Of Issuance Costs
StockAndPrefundedWarrantsIssuedDuringPeriodValuePrivatePlacementNetOfIssuanceCosts
866000 usd
CY2023Q1 atxi Stock Issued During Period Value License Expense
StockIssuedDuringPeriodValueLicenseExpense
1230000 usd
CY2023Q1 atxi Stock Issued During Period Value Exercise0f Warrants
StockIssuedDuringPeriodValueExercise0fWarrants
0 usd
CY2023Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-66000 usd
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7536000 usd
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-2157000 usd
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
3451000 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
569000 usd
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-2861000 usd
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1159000 usd
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-7602000 usd
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-2861000 usd
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
11000 usd
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
569000 usd
CY2023Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
878000 usd
CY2022Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0 usd
CY2023Q1 atxi Issuance Of Stock For Licenses Acquired
IssuanceOfStockForLicensesAcquired
1230000 usd
CY2022Q1 atxi Issuance Of Stock For Licenses Acquired
IssuanceOfStockForLicensesAcquired
0 usd
CY2023Q1 atxi Issuance Of Stock Under Founders Agreement
IssuanceOfStockUnderFoundersAgreement
72000 usd
CY2022Q1 atxi Issuance Of Stock Under Founders Agreement
IssuanceOfStockUnderFoundersAgreement
0 usd
CY2023Q1 us-gaap Increase Decrease In Due From Other Related Parties Current
IncreaseDecreaseInDueFromOtherRelatedPartiesCurrent
13000 usd
CY2022Q1 us-gaap Increase Decrease In Due From Other Related Parties Current
IncreaseDecreaseInDueFromOtherRelatedPartiesCurrent
-90000 usd
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
61000 usd
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
16000 usd
CY2023Q1 atxi Increase Decrease In Accrued Licenses Acquired
IncreaseDecreaseInAccruedLicensesAcquired
3000000 usd
CY2022Q1 atxi Increase Decrease In Accrued Licenses Acquired
IncreaseDecreaseInAccruedLicensesAcquired
0 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1573000 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1930000 usd
CY2023Q1 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
3101000 usd
CY2022Q1 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
0 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3101000 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
1528000 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-1930000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
6708000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
3763000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
8236000 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1833000 usd
CY2023Q1 atxi Unpaid Research And Development Licenses Acquired
UnpaidResearchAndDevelopmentLicensesAcquired
3000000 usd
CY2022Q1 atxi Unpaid Research And Development Licenses Acquired
UnpaidResearchAndDevelopmentLicensesAcquired
0 usd
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
25000000
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-88100000 usd
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7200234
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
38078
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Use of Estimates</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company's consolidated financial statements include certain amounts that are based on management's best estimates and judgements. The Company's significant estimates include, but are <em style="font: inherit;">not</em> limited to, fair value of warrants, stock-based compensation, common stock issued to acquire licenses, accrued expenses, provisions for income taxes and contingencies. Due to the uncertainty inherent in such estimates, actual results <em style="font: inherit;"> may </em>differ from these estimates.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"/>
CY2019Q4 atxi Contractual Obligation Development Expense
ContractualObligationDevelopmentExpense
81500000 usd
CY2019Q4 atxi Contractual Obligation Commercial Expense
ContractualObligationCommercialExpense
151000000 usd
CY2022Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
4137916
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
330000 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
129000 usd
CY2023Q1 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
287000 usd
CY2022Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
199000 usd
CY2023Q1 atxi Accrued Contingent Fee
AccruedContingentFee
0 usd
CY2022Q4 atxi Accrued Contingent Fee
AccruedContingentFee
208000 usd
CY2023Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1221000 usd
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
413000 usd
CY2023Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1838000 usd
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
949000 usd

Files In Submission

Name View Source Status
0001437749-23-014236-index-headers.html Edgar Link pending
0001437749-23-014236-index.html Edgar Link pending
0001437749-23-014236.txt Edgar Link pending
0001437749-23-014236-xbrl.zip Edgar Link pending
atxi-20230331.xsd Edgar Link pending
atxi-20230331_cal.xml Edgar Link unprocessable
atxi-20230331_def.xml Edgar Link unprocessable
atxi20230331_10q.htm Edgar Link pending
ex_502209.htm Edgar Link pending
ex_502210.htm Edgar Link pending
ex_502211.htm Edgar Link pending
ex_502212.htm Edgar Link pending
ex_519672.htm Edgar Link pending
ex_519673.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
image1.jpg Edgar Link pending
image2.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
atxi-20230331_lab.xml Edgar Link unprocessable
atxi-20230331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
atxi20230331_10q_htm.xml Edgar Link completed